Embed Size (px)
Citation preview
Objective Diagnostics for Parkinson’s Disease
®
Our Name - Brain Backups
High-Resolution Brain Imaging Platform
Nondestructive, noninvasive, whole brain in vivo imaging at the connectome level
Current methods for whole brain imaging
● Current methods of whole brain in vivo imaging do not provide adequate resolution.
● Methods providing adequate resolution have incomplete coverage, or require
destructive slicing of the brain.
First Target: An Early & Accurate Parkinson’s Disease Diagnostic
The Solution - AptaMark
Accurate & Objective
Dopamine D2R test
AptaMark will be the first contrast agent with a single
cell resolution, allowing neurodegeneration in the
substantia nigra and other relevant areas can be tracked
objectively.
• First Objective Diagnostic for PD
• Enables early detection
• Tracks degradation directly at source
• Differentiates amongst PD subtypes
• Non destructive/non invasive
• 1 micron resolution
● 34 drugs in development
● Aging population
● $26B in US Healthcare Costs
● $3B in PD specific treatment “Large potential market for neurotechnology”
- NeuroTech Business Report
The Opportunity
PD diagnosis and mid-treatment imaging demand will
continue to grow.
Competitive Analysis
Cost Accuracy Early
Detection
Objectivity Resolution
Doctors Low ~76% Clinical No N/A
Movement
Software
$100 Low Clinical Yes N/A
CT $700 Moderate Clinical No 1mm
MRI $1,200 ~85% Clinical No 1mm
DaTscan $5,000 ~84% Clinical No 1mm
AptaMark $2,800 Aim >90% Preclinical Yes 1µm
The Competitors
New contrast agents are being developed every year.
All lack the specificity of AptaMark and many rely on expensive small molecule chemistry &
approvals process and often less precise methods.
DaTscan is a SPECT iodine-123 contrast agent that
images dopamine transporter and allows clinicians to
distinguish essential tremor from PD.
AptaMark permits imaging at 1 micron resolution,
100X better than MRI; offers specificity to subtypes
of dopamine receptors; uses same GE imaging
hardware provides better diagnosis.
Revenue Projections
Assuming a 5% market share in Y4, we can reasonably expect close to
$4M per year in initial diagnostic revenue.
If AptaMark is used in treatment management, revenue growth becomes exponential.
40,000 out of 1.5M total patients tested twice a year will result in $100M of revenue.
Market Share RevenueCost per Test
As costs decrease with scale, EBITA will grow from
11% to more than 48% as quantity grows past 1000.
Potential Partnerships
From MRI to aptamers, a lot of companies work with relevant
technology. We are continuing an active outreach process to
engage researchers and clinicians alike with our technology.
The Team
Mihai Dinulescu
Russell Hanson Jason Fuller
Robert Cunningham Webster Heffern
...to demonstrate Parkinson’s can be imaged at the source.
● $2.5M for further optimization & research deployment
● Potentially positive ROI from research revenue alone
● $30M+ for Phase I & Phase II toxicology trials
● Exit after proven safety & efficacy
● Clinical trials performed through partnerships
What we are asking for...
30,000 Validation and Optimization 1.2%
20,000 Scale up batches 0.8%
50,000 At scale batches 2%
400,000 Real estate: laboratory & office space 16%
250,000 Main laboratory equipment 10%
500,000 In vivo validation FDA 510K 20%
100,000 Licensing to established vendors 4%
1,100,000 Personnel and marketing 44%
50,000 To be budgeted and incidentals 2%
Total:
2,500,000 100%
Appendix: Financial I - $2.5M Series A Breakdown
Appendix: Financial II - Research Revenue
Core product is a recurring cost consumable ● Initial product cost*: $1,300/test
● Scale product costA: $550/test
● Cost to consumer: $2,800/test
● Break-even point T: ~1,200 tests
● Assuming an MRI cost of ~$1,000, AptaMark is competitive with DaTscan
for diagnostic and treatment management imaging
● Even with 80% production profit margin, AptaMark remains 100x more
rentable than current destructive research methods
A Cost estimates are for total cost of production, manufacturing, and overhead at appropriate stage
* Assumes 200+ test batches T At scale cost, associated profit margin, and 2.5M Series A
Appendix: Development Timeline
Appendix: Financial III - Ancillary Markets
Research Products
● Alzheimer’s
● Autism
● Huntington’s
● Schizophrenia
● Additional research
● Obsessive Compulsive Disorder
● Etc...
Appendix: Science I - About Aptamers
Advantages of Using Aptamers
● Very small, very precise ~ 1 micron
● Chemically synthesized, no bioreactors
● Easy to ship, safe to handle
● Cross blood brain barrier
● Don’t trigger the neurons they bind to
● Safely cleared
Appendix: Science II - Technology Details
Gold nanoparticle with attached D2-specific ligand
Rat knee imaged at 3 microns (0.003mm voxel)
Nanoparticle uniformity validation using dynamic light
scattering
